Manulife (Manufacturers Life Insurance)
HRTX icon

Manulife (Manufacturers Life Insurance)’s Heron Therapeutics HRTX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.8K Sell
45,988
-2,671
-5% -$3.1K ﹤0.01% 2768
2025
Q4 		$63.3K Sell
48,659
-3,309
-6% -$4.09K ﹤0.01% 2783
2025
Q3 		$65.5K Sell
51,968
-189,080
-78% -$300K ﹤0.01% 2850
2025
Q2 		$499K Buy
241,048
+11,716
+5% +$23.9K ﹤0.01% 2178
2025
Q1 		$505K Buy
229,332
+185,047
+418% +$359K ﹤0.01% 2141
2024
Q4 		$67.8K Sell
44,285
-227
-0.5% -$368 ﹤0.01% 2890
2024
Q3 		$88.6K Sell
44,512
-1,259
-3% -$3.01K ﹤0.01% 2891
2024
Q2 		$160K Buy
45,771
+6,328
+16% +$19.4K ﹤0.01% 2685
2024
Q1 		$109K Sell
39,443
-1,478
-4% -$3.71K ﹤0.01% 2757
2023
Q4 		$69.6K Buy
40,921
+21,318
+109% +$23.5K ﹤0.01% 2892
2023
Q3 		$20.2K Buy
+19,603
New +$27.9K ﹤0.01% 2964
2023
Q2 		– Sell
-41,756
Closed -$63.1K – 3008
2023
Q1 		$63.1K Hold
41,756
– – ﹤0.01% 2829
2022
Q4 		$104K Sell
41,756
-131
-0.3% -$422 ﹤0.01% 2789
2022
Q3 		$177K Sell
41,887
-1,262
-3% -$4.94K ﹤0.01% 2636
2022
Q2 		$120K Buy
43,149
+3,549
+9% +$14.3K ﹤0.01% 2847
2022
Q1 		$227K Sell
39,600
-9,517
-19% -$69.6K ﹤0.01% 2689
2021
Q4 		$448 Buy
49,117
+181
+0.4% +$1.85K ﹤0.01% 2336
2021
Q3 		$523K Sell
48,936
-3,479
-7% -$42.4K ﹤0.01% 2253
2021
Q2 		$813K Buy
52,415
+3,377
+7% +$53.7K ﹤0.01% 2112
2021
Q1 		$795K Sell
49,038
-2,370
-5% -$42.3K ﹤0.01% 2016
2020
Q4 		$1.09M Buy
51,408
+1,899
+4% +$33K ﹤0.01% 1767
2020
Q3 		$734K Sell
49,509
-937
-2% -$14.6K ﹤0.01% 1803
2020
Q2 		$719K Sell
50,446
-1,016
-2% -$16.7K ﹤0.01% 1777
2020
Q1 		$604K Buy
51,462
+8,870
+21% +$167K ﹤0.01% 1743
2019
Q4 		$1M Sell
42,592
-1,543
-3% -$34.1K ﹤0.01% 1681
2019
Q3 		$865K Sell
44,135
-87
-0.2% -$1.6K ﹤0.01% 1718
2019
Q2 		$822K Buy
44,222
+1,093
+3% +$21.8K ﹤0.01% 1745
2019
Q1 		$1.05M Buy
43,129
+837
+2% +$21.9K ﹤0.01% 1658
2018
Q4 		$1.1M Sell
42,292
-705
-2% -$19.4K ﹤0.01% 1554
2018
Q3 		$1.36M Sell
42,997
-2,390
-5% -$89K ﹤0.01% 1616
2018
Q2 		$1.76M Buy
45,387
+6,419
+16% +$204K ﹤0.01% 1547
2018
Q1 		$1.08M Buy
38,968
+5,349
+16% +$121K ﹤0.01% 1795
2017
Q4 		$608K Sell
33,619
-559
-2% -$9.12K ﹤0.01% 2193
2017
Q3 		$553K Sell
34,178
-563
-2% -$8.83K ﹤0.01% 2210
2017
Q2 		$482K Buy
34,741
+8,135
+31% +$118K ﹤0.01% 2321
2017
Q1 		$399K Buy
26,606
+5,098
+24% +$70.6K ﹤0.01% 2344
2016
Q4 		$282K Buy
21,508
+441
+2% +$6.92K ﹤0.01% 2524
2016
Q3 		$363K Sell
21,067
-37
-0.2% -$686 ﹤0.01% 2306
2016
Q2 		$381K Buy
21,104
+2,585
+14% +$50.5K ﹤0.01% 2210
2016
Q1 		$359K Buy
18,519
+368
+2% +$7.26K ﹤0.01% 2200
2015
Q4 		$485 Buy
18,151
+199
+1% +$5.32K ﹤0.01% 2047
2015
Q3 		$438 Buy
17,952
+2,865
+19% +$95.5K ﹤0.01% 2076
2015
Q2 		$470 Sell
15,087
-610
-4% -$11.5K ﹤0.01% 2162
2015
Q1 		$228 Sell
15,697
-511
-3% -$5.76K ﹤0.01% 2635
2014
Q4 		$163 Buy
16,208
+362
+2% +$2.95K ﹤0.01% 2789
2014
Q3 		$132 Buy
15,846
+2,407
+18% +$22.4K ﹤0.01% 2925
2014
Q2 		$166K Buy
+13,439
New +$161K ﹤0.01% 2866

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s HRTX Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Heron Therapeutics (HRTX) stake by 5.5% in Q1 2026, selling an estimated $3.1K and leaving 45,988 shares worth $36.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2768.

Manulife (Manufacturers Life Insurance) first reported a position in HRTX in Q2 2014 and has held it in 47 quarters since. The position peaked at $1.76M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 45,988 shares of Heron Therapeutics worth $36.8K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 2,671 Heron Therapeutics shares in Q1 2026, an estimated $3.1K.
  • Heron Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2768 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Heron Therapeutics in Q2 2014 and has held it in 47 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Heron Therapeutics position peaked at $1.76M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.